If Merck's NYSE price is falling in an otherwise rising market again tomorrow morning -- and/or falling significantly more than its peers -- as it was today, I may offer a few thoughts on, and some analysis of the recent developments in
the fifth Fosamax® ONJ bellwether trial (of a scheduled seven) -- still underway in Manhattan's federal District courthouse.
There have been some interesting disputes, here in week two, about what may be offered as evidence on behalf of Rhoda Scheinberg, the plaintiff -- to support her Fosamax ONJ design defect and failure to warn claims.
We shall see -- do tune in tomorrow, but the trial is likely to continue well into next week.
No comments:
Post a Comment